Document is current
Any future updates will be listed below
-
Authors
Lee, Jeoung Eun
Lee, Chang Woo
Han, A-Reum
Kim, Jina
Lee, Dong Ryul https://orcid.org/0000-0003-1534-4810
-
Funding
Funding for this research was provided by:
the National Research Foundation of Korea (2019R1A6A1A03032888, No.2022M3A9I2082319, and No.2022R1A2C1004718)
- License Information
-
More Information
Article History
Received: 29 October 2024
Accepted: 18 July 2025
First Online: 26 July 2025
Declarations
:
: All experiments using hESCs were performed with authorization from the Institutional Review Board for Human Research at CHA University, Seongnam, Korea (title of the approve project: Development of cell-therapy product for the diabetes using embryonic stem cell-derived Sertoli Cells; name of the institutional approval committee: CHA University Institutional Review Board; Approval number and date: 1044308-201712-LR-050-03 (Jun. 5, 2019), 1044308-201712-LR-050-04 (Jun. 8, 2020), 1044308-201712-LR-050-06 (Jul. 14, 2021), 1044308-201712-LR-050-07,08 (Jun. 2, 2022), and 1044308-201712-LR-050-09 (Jun. 9, 2023)).The experiments using donated human periperal blood were approved by the CHA University Institutional Review Board (title of the approve project: Study for the immune reaction of human cells in vitro and i n vivo (humanized mice) with various HLA type matched blood cells derived from donated human peripheral blood and bone marrow derived blood; name of the institutional approval committee: CHA University Institutional Review Board; Approval number and date: 1044308-201803-BR-014-02 (Apr. 23,2018) and 1044308-201803-BR-014-03 (May 8, 2019)).The experimental protocols were approved by the Institutional Animal Care and Use Committee of CHA University (title of the approval project: Development of type 1 diabetes treatment using stem cell-derived insulin-secreting cells; name of the institutional approval committee: CHA University IACUC; Approval number and date: IACUC210110 (Aug. 2, 2021), IACUC220139 (Aug. 3, 2022), and IACUC230120 (Jul. 13, 2023)).The human Sertoli cells (hSCs; #4520, ScienCell, Carlsbad, CA) used for the experimental control were obtained from donors and written informed consent were obtained from the donors ( ). Also, human bone marrow-derived mesenchymal stem cells (hBM-MSCs; PT-2501, Lonza, Walkersville, MD) used for the experimental control were obtained from donors and written informed consent were obtained from the donors ( ).
: Not applicable.
: The authors declare that they have no conflict of interest.
